Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03256045 · OUTCOME

Synergy of Panobinostat and Dexamethasone in Combination, Per Subject

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
CI score
Interval / dispersion
Not reported
Time frame
At baseline

What was measured

Concentration of panobinostat and dexamethasone in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = (\[D1\] in the combination / \[D1\] alone) + (\[D2\] in the combination / \[D2\] alone). Key: CI = 1 no synergy; CI\<1 synergy; CI\>1 antagonism.

Analysis population: CI score was not reported for subject MM-82

Groups in this outcome

Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone

Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone8

Reported measurements

Subject MM-91
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1.3Not reportedNot reportedNot reportedNot reported
Subject MM-92
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone2.6Not reportedNot reportedNot reportedNot reported
Subject MM-95
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1.4Not reportedNot reportedNot reportedNot reported
Subject MM-96
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.6Not reportedNot reportedNot reportedNot reported
Subject MM-98
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1.2Not reportedNot reportedNot reportedNot reported
Subject MM-99
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone0.9Not reportedNot reportedNot reportedNot reported
Subject MM-109
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone4.6Not reportedNot reportedNot reportedNot reported
Subject MM-111
Values in CI score · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone1.2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1.3
    title
    Subject MM-91
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2.6
    title
    Subject MM-92
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1.4
    title
    Subject MM-95
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        0.6
    title
    Subject MM-96
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1.2
    title
    Subject MM-98
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0.9
    title
    Subject MM-99
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        4.6
    title
    Subject MM-109
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1.2
    title
    Subject MM-111
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
Concentration of panobinostat and dexamethasone in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = (\[D1\] in the combination / \[D1\] alone) + (\[D2\] in the combination / \[D2\] alone). Key: CI = 1 no synergy; CI\<1 synergy; CI\>1 antagonism.
groups
  1. description
    Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
param Type
NUMBER
population Description
CI score was not reported for subject MM-82
reporting Status
POSTED
time Frame
At baseline
title
Synergy of Panobinostat and Dexamethasone in Combination, Per Subject
type
PRIMARY
unit Of Measure
CI score

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice